A Phase I-II Study of NBTXR3 Activated by Stereotactic Body Radiation Therapy (SBRT) in the Treatment of Liver Cancers

Trial Profile

A Phase I-II Study of NBTXR3 Activated by Stereotactic Body Radiation Therapy (SBRT) in the Treatment of Liver Cancers

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 04 Apr 2017

At a glance

  • Drugs NBTXR 3 (Primary)
  • Indications Liver cancer
  • Focus Adverse reactions
  • Sponsors Nanobiotix
  • Most Recent Events

    • 04 Apr 2017 Nanobiotix aims to complete patient recruitment for the Phase I part of this trial, and may proceed to select the patient population for the dose-expansion part of the trial (Phase II) before the end of 2017, according to a company media release.
    • 14 Dec 2016 Preliminary results published in the Nanobiotix Media Release.
    • 29 Apr 2016 According to Nanobiotix media release, company expects the first intermediate results from this study in liver cancers (HCC and liver metastases) in the different patient's populations to be announced in H2 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top